NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/12/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,647.23 mln
Float44.43 mln
Earnings Date08/19/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
59.22
Strong upside
Relative Strength
96
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-22.80
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Enliven Therapeutics is a drug development company working to create new treatments for cancer patients. Founded in 2019 and based in Boulder, Colorado, the company is currently running early-stage clinical trials for two experimental medicines ? one targeting a form of leukemia and another aimed at lung cancer and related tumor types. Both treatments are designed as precisely targeted drugs intended to block the specific biological signals that drive cancer growth.
